Navegando por Assunto "Meningioma"

Agora exibindo 1 - 4 de 4

Acesso aberto (Open Access)
Alterações genéticas e epigenéticas em meningiomas na população paraense
(Universidade Federal do Pará, 2013-07-17) BASTOS, Carlos Eduardo Matos Carvalho; ANSELMO, Nilson Praia; http://lattes.cnpq.br/6518287721873199; NAGAMACHI, Cleusa Yoshiko; http://lattes.cnpq.br/8887641213110093
Meningiomas are the most common intracranial tumors that originate from the meninges surrounding the brain and spinal cord. Despite meningiomas were among the first solid neoplasms to be studied cytogenetically, little is known about their genetic and epigenetic profile. This study aimed to investigate genetic and epigenetic alterations that could contribute to tumor initiation and progression in meningiomas in the population of Pará, Brazil. This thesis is subdivided into three chapters. In Chapter I we investigated the association between the MTHFR C677T and meningioma in 23 patients in the population of Pará. A total of 96 healthy individuals with no previous pre-neoplastic lesions were selected for the control group. This association was not found. Although not statistically significant, our observation suggests that the TT genotype increases the risk of developing meningioma when compared to CC genotype. In Chapter II we evaluated the methylation pattern in two members of microRNA124 family in meningiomas in the population of Pará. Hypermethylation of the promoter region of miRN124a2 and miRNA124a3 appears to be a frequent event, as was found in 73.9% and 69.56% of the samples, respectively. In Chapter III, we analyzed the methylation pattern of the APC, BRCA1, CDH1, CDH13, CDKN2A, DAPK1, ESR1, FHIT, GSTP1, MGMT, MLH1, NEUROG1, PDLIM4, PTEN, Rb, RASSF1, RUNX3, SOCS1, TIMP3, TP73, VHL and WIF1 genes in a grade I and in a grade II meningiomas through an assay developed by MethylScreen. Pattern of methylation of CDKN2B was also analyzed in 25 patients with meningioma through bisulfite conversion, PCR and direct sequencing. RASSF1A was methylated in 16.73% and 63.66% of the CpG sites analyzed in the grade I and grade II meningioma, respectively. RUNX3 is methylated only in grade II meningioma in 52.88% of the CpG sites analyzed. Our results point to the importance of epigenetic changes in tumorigenesis and tumor progression in meningiomas.
Acesso aberto (Open Access)
Análise de alterações no número de cópias envolvendo os cromossomos 1p e 22 em meningiomas de baixo grau
(Universidade Federal do Pará, 2013-12-13) SILVA, Geanny Pereira da; OLIVEIRA, Edivaldo Herculano Correa de; http://lattes.cnpq.br/0094007714707651
Meningiomas are the second most common type of primary brain tumor, originating in the meninges covering the brain and spinal cord. They show slow growth, and are found more often in the CNS, being benign in most case, although there are also cases of meningiomas classified as malignant. At the cytogenetic level, meningiomas are the most well studied tumors in humans: studies in CNS tumors have shown that most cases had chromosomal abnormalities, and the most common alterations in theis type of tumor are the loss of one copy of chromosome 22 and deletion of the short arm of chromosome 1. These alterations have been associated with the tumorigenesis process, because they are found mostly in low-grade tumors, particularly deletions involving chromosome 22. Thus, the aim of this study was to analyze the occurrence of copy number alterations (CNAs) involving chromosomes 1p and 22 meningiomas grade I and II, and in addition to verifying the existence of other recurrent rearrangements through the application of high resolution comparative genomic hybridization (array - CGH ). Tumor samples were collected from eight patients. All samples showed gains and losses of various chromosomal segments. Except for one case, all others showed, in different degrees though, more deletions than amplifications. Loss of 1p segments was observed in all samples. Some CNAs were recurrent, being found up to six out of the eight cases. Pair 22 showed CNV in all samples, but the total monosomy was observed in only two of the eight samples. The global analysis of CNAs in all samples showed that, although changes 1p and 22 were the most frequent observed alterations, as expected, other genomic regions had also alterations in various samples, indicating a possible involvement of these modifications in the process of tumorigenesis and tumor progression. For instance, alterations in pairs 9, 12 and 17, have been observed in other studies and were correlated with atypical and anaplastic meningiomas. Our data indicate the existence of a larger number of genomic alterations in low-grade meningiomas, disagreeing partly with the assumption that these tumors are characterized by a small number of changes, usually involving pair 22 and, less frquently, loss of 1p. However, the fact that these tumors present alterations that are classically found in meningiomas, even benign, such as deletions in 1p and 22q, may be an indication that these changes must be linked with the early events of origin in meningiomas, as already suggested several times by other authors . In conclusion, these alterations remain important markers in meningiomas, and the relationships of these and other CNAs with the response to different treatments and recurrences should be the next step after cytogenomic characterization based on array-CGH has been completed.
Acesso aberto (Open Access)
Análises dos genes TP53, PTEN, IDH1 e IDH2 em tumores não gliais do sistema nervoso humano
(Universidade Federal do Pará, 2016-06-17) LOPES, Cleiton Mendes; ANSELMO, Nilson Praia; http://lattes.cnpq.br/6518287721873199
Despite the considerable incidence, studies of genetic changes in gene TP53, PTEN, IDH2 and IDH1, in not glial tumors are rare and, in some cases, nonexistent. Glial tumors are usually not classified as benign and rarely evolve to malignancy, with different classifications, effects and locations. The tumor suppressor genes and response to DNA damage, TP53 and PTEN are among the most commonly mutated gene in human tumors. The genes IDH1 and IDH2 are involved in cell metabolism and also were frequently found mutated in gliomas, melanomas and leukemias, currently being considered as good markers for gliomas. Genetic analyzes were performed in those genes, in order to verify that are associated with the etiology and/or progression of non-glial tumors of Human Nervous System (HNS). SSCPPCR techniques for the amplification of the region of interest and mutational screening of samples for subsequent sequencing were used. We analyzed 37 samples of non-glial tumors (14 schwannomas, meningiomas 3, 4 Medulloblastomas, 2 neurocytomas and 14 metastases of Central Nervous System (CNS). Only the gene IDH1 polymorphisms presented on the SSCP 12 (32.4%) samples, and then subjected to sequencing. However, sequencing reactions were satisfactory in only 5 samples, of the polymorphic, (1 metastasis, meningioma 1 and 3 schwannomas). Analysis of these samples have identified 5 different mutations, one present in all, one transversion T → A in codon 106 of exon 4 of the IDH1 gene resulting in amino acid substitution of threonine by serine. Were also identified other mutations in noncoding regions (intron 4) of gene IDH1 in two of these samples. The mutations found in our study had not yet been reported in the literature. Our results indicate the participation the gene IDH1 in the pathogenesis of these tumors.
Acesso aberto (Open Access)
Epigenetic alterations in human brain tumors in a Brazilian population
(2006) ANSELMO, Nilson Praia; BELLO, Maria Josefa; GONZALEZ-GOMEZ, Pilar; DIAS, Luis Antonio Araújo; ALMEIDA, José Reinaldo Walter de; SANTOS, Marcelo José dos; HERRANZ, Juan Antonio Rey; CASARTELLI, Cacilda
Aberrant methylation of CpG islands located in promoter regions represents one of the major mechanisms for silencing cancer-related genes in tumor cells. We determined the frequency of aberrant CpG island methylation for several tumor-associated genes: DAPK, MGMT, p14ARF, p16INK4a, TP73, RB1 and TIMP-3 in 55 brain tumors, consisting of 26 neuroepithelial tumors, 6 peripheral nerve tumors, 13 meningeal tumors and 10 metastatic brain tumors. Aberrant methylation of at least one of the seven genes studied was detected in 83.6% of the cases. The frequencies of aberrant methylation were: 40% for p14ARF, 38.2% for MGMT, 30.9% for, p16INK4a, 14.6% for TP73 and for TIMP-3, 12.7% for DAPK and 1.8% for RB1. These data suggest that the hypermethylation observed in the genes p14ARF, MGMT and p16INK4a is a very important event in the formation or progression of brain tumors, since the inactivation of these genes directly interferes with the cell cycle or DNA repair. The altered methylation rate of the other genes has already been reported to be related to tumorigenesis, but the low methylation rate of RB1 found in tumors in our sample is different from that so far reported in the literature, suggesting that perhaps hypermethylation of the promoter is not the main event in the inactivation of this gene. Our results suggest that hypermethylation of the promoter region is a very common event in nervous system tumors.